Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin via OptiNose in ASD
NCT02414503Phase 2Completed
- Sponsor
- OptiNose
- Start
- Apr 2015
- Primary completion
- Feb 2016
- Countries
- 1
01
Overview
A Phase 2 trial of oxytocin nasal spray in Autism Spectrum Disorder (ASD), sponsored by OptiNose. Started Apr 2015; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02414503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02414503.